SLTE-1009 / Slate Medicines - LARVOL DELTA

Slate starts up with $130M and a headache drug from China (BioPharma Dive) - "Slate’s drug, SLTE-1009, is a subcutaneous injection that could be given at home....Phase 1 testing should start in mid-2026."

Financing • New P1 trial • Migraine